Mutant p53 Drives Invasion by Promoting Integrin Recycling

Cell

Volumn 139, Issue 7, 2009, Pages 1327-1341

  Muller, Patricia A J ^a   Caswell, Patrick T ^a   Doyle, Brendan ^a   Iwanicki, Marcin P ^b   Tan, Ee H ^a   Karim, Saadia ^a   Lukashchuk, Natalia ^a   Gillespie, David A ^a   Ludwig, Robert L ^a   Gosselin, Pauline ^b   Cromer, Anne ^b   Brugge, Joan S ^b   Sansom, Owen J ^a   Norman, Jim C ^a   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HUMDISEASE

Indexed keywords

ALPHA5 INTEGRIN; BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; MUTANT PROTEIN; PROTEIN P53; PROTEIN P63; RAB PROTEIN;

ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 72249100428     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.11.026     Document Type: Article

References (38)

1. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137 (2009) 87-98
2. Attardi L.D., and Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell. Mol. Life Sci. 55 (1999) 48-63
3. Blagosklonny M.V. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J. 14 (2000) 1901-1907
4. Bourdon J.C. p53 and its isoforms in cancer. Br. J. Cancer 97 (2007) 277-282
5. Brockbank E.C., Bridges J., Marshall C.J., and Sahai E. Integrin beta1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. Br. J. Cancer 92 (2005) 102-112
6. Brosh R., and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9 (2009) 701-713
7. Cantor J.P., Iliopoulos D., Rao A.S., Druck T., Semba S., Han S.Y., McCorkell K.A., Lakshman T.V., Collins J.E., Wachsberger P., et al. Epigenetic modulation of endogenous suppressor expression in lung cancer xenografts suppresses igenicity. Int. J. Cancer 120 (2007) 24-31
8. Carroll D.K., Carroll J.S., Leong C.O., Cheng F., Brown M., Mills A.A., Brugge J.S., and Ellisen L.W. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat. Cell Biol. 8 (2006) 551-561
9. Caswell P., and Norman J. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol. 18 (2008) 257-263
10. Caswell P.T., Spence H.J., Parsons M., White D.P., Clark K., Cheng K.W., Mills G.B., Humphries M.J., Messent A.J., Anderson K.I., et al. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev. Cell 13 (2007) 496-510
11. Caswell P.T., Chan M., Lindsay A.J., McCaffrey M.W., Boettiger D., and Norman J.C. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J. Cell Biol. 183 (2008) 143-155
12. Cho Y., Gorina S., Jeffery P.D., and Pavletich N.P. Crystal structure of a p53 suppressor-DNA complex: understanding igenic mutations. Science 265 (1994) 346-355
13. Epstein C.B., Attiyeh E.F., Hobson D.A., Silver A.L., Broach J.R., and Levine A.J. p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in humans. Oncogene 16 (1998) 2115-2122
14. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., Yang A., McKeon F., and Jacks T. Predisposition in mice mutant for p63 and p73: evidence for broader suppressor functions for the p53 family. Cancer Cell 7 (2005) 363-373
15. Gaiddon C., Lokshn M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-reulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21 (2001) 1874-1887
16. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., and Berns A. Synergistic suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29 (2001) 418-425
17. Kupfer A., Louvard D., and Singer S.J. Polarization of the Golgi apparatus and the microtubule-organizing center in cultured fibroblasts at the edge of an experimental wound. Proc. Natl. Acad. Sci. USA 79 (1982) 2603-2607
18. Lane D.P. p53 and human cancers. Br. Med. Bull. 50 (1994) 582-599
19. Lang G.A., Iwakuma T., Suh Y.-A., Liu G., Rao A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain-of-function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004) 861-872
20. Li Y., and Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 26 (2007) 2220-2225
21. Lin J., Teresky A.K., and Levine A.J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10 (1995) 2387-2390
22. Marsh V., Winton D.J., Williams G.T., Dubois N., Trumpp A., Sansom O.J., and Clarke A.R. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat. Genet. 40 (2008) 1436-1444
23. Matas D., Sigal A., Stambolsky P., Milyavsky M., Weisz L., Schwartz D., Goldfinger N., and Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 20 (2001) 4163-4172
24. Muthuswamy S.K., Li D., Lelievre S., Bissell M.J., and Brugge J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 3 (2001) 785-792
25. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., and Jacks T. Mutant p53 gain-of-function in two mouse models of Li-Fraumeni syndrome. Cell 119 (2004) 847-860
26. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
27. Roberts M., Barry S., Woods A., van der Sluijs P., and Norman J. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr. Biol. 11 (2001) 1392-1402
28. Sansom O.J., Reed K.R., Hayes A.J., Ireland H., Brinkmann H., Newton I.P., Batlle E., Simon-Assmann P., Clevers H., Nathke I.S., et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 18 (2004) 1385-1390
29. Sansom O.J., Meniel V., Wilkins J.A., Cole A.M., Oien K.A., Marsh V., Jamieson T.J., Guerra C., Ashton G.H., Barbacid M., et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 14122-14127
30. Schwartz M.A., and Ginsberg M.H. Networks and crosstalk: integrin signalling spreads. Nat. Cell Biol. 4 (2002) E65-E68
31. Seton-Rogers S.E., Lu Y., Hines L.M., Koundinya M., LaBaer J., Muthuswamy S.K., and Brugge J.S. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 101 (2004) 1257-1262
32. Sigal A., and Rotter V. Oncogenic mutations of the p53 suppressor: the demons of the guardian of the genome. Cancer Res. 60 (2000) 6788-6793
33. Soussi T. The p53 suppressor gene: from molecular biology to clinical investigation. Ann. N Y Acad. Sci. 910 (2000) 121-137
34. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., et al. Physical interaction with human derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277 (2002) 18817-18826
35. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
36. Vousden K.H., and Prives C. Blinded by the light: the growing complexity of p53. Cell 137 (2009) 413-431
37. White D.P., Caswell P.T., and Norman J.C. alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J. Cell Biol. 177 (2007) 515-525
38. Zhang J., Liu X., Datta A., Govindarajan K., Tam W.L., Han J., George J., Wong C., Ramnarayanan K., Phua T.Y., et al. RCP is a human breast cancer-promoting gene with Ras-activating function. J. Clin. Invest. 119 (2009) 2171-2183